Here are two analogies to describe Prime Medicine:

• Prime Medicine is like CRISPR Therapeutics, but with a gene-editing technology designed to fix a wider variety of genetic errors.
• Prime Medicine is like Beam Therapeutics, but with a gene-editing tool capable of correcting a much broader range of genetic mutations beyond just single-base changes.

• Prime Editing Technology: A proprietary gene editing platform designed to precisely correct diverse genetic mutations underlying human diseases.
• Genetic Therapies: A pipeline of one-time curative treatments in development, utilizing Prime Editing to address a wide spectrum of human diseases.

Based on the provided company description, Prime Medicine (PRME) is a biotechnology company in the research and development phase. Its core focus is on developing a new class of genetic therapies, Prime Editors. The description explicitly states that this technology "is not yet clinically validated for human therapeutic use."

Therefore, Prime Medicine does not currently have major customers, whether they be other companies or individual patients, as its products are not yet commercialized or approved for sale. The company is actively developing its therapeutic pipeline rather than selling existing products or services.

Allan Reine, MD Chief Executive Officer

• Allan Reine, MD, was appointed Chief Executive Officer of Prime Medicine in May 2025, having previously served as the company's Chief Financial Officer since joining in January 2024.
• He concurrently serves as the principal financial officer.
• Prior to Prime Medicine, Dr. Reine held CFO roles at Foghorn Therapeutics and Pieris Pharmaceuticals.
• He also serves as Chairman of the Board of ONK Therapeutics.
• Earlier in his career, he managed various healthcare portfolios, focusing on biotechnology and pharmaceutical companies, at firms such as Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital, and Alexandra Investment Management.
• He began his career in biotechnology investment banking and equity research at CIBC World Markets.

Mohammed Asmal, MD, PhD Chief Medical Officer

• Mohammed Asmal, MD, PhD, is the Chief Medical Officer at Prime Medicine.
• He is a physician-scientist with an AB in biology and biomedical engineering from Harvard University and an MD-PhD in molecular and cellular biology from Columbia University.
• Dr. Asmal trained in internal medicine and infectious diseases at the Brigham and Women's and Massachusetts General Hospitals.
• He previously led trials in oncology and hepatitis C at Vertex Pharmaceuticals, advancing multiple small molecules into the clinic through Phase II.
• Subsequently, he led the clinical development team at bluebird bio, overseeing lentiviral-based gene therapy programs that led to the first approval of a gene therapy for a hemoglobinopathy.

Matthew Hawryluk, PhD Chief Business Officer

• Matthew Hawryluk, PhD, joined Prime Medicine as Chief Business Officer in 2025.
• Before joining Prime Medicine, he served as Chief Business Officer at AIRNA Corporation, an RNA-editing company, where he was responsible for corporate and business development, finance, and legal functions, and helped secure an oversubscribed $155 million Series B financing.
• For nearly a decade, Dr. Hawryluk was Executive Vice President and Chief Business Officer, Head of Legal, and Boston Site Head at Gritstone bio, Inc. (NASDAQ: GRTS), guiding its growth from an early-stage company to a public entity and spearheading its expansion into infectious diseases.
• He has led transactions exceeding $2.5 billion in potential value, including collaborations with Gilead Sciences and bluebird bio.

Ann Lee, PhD Chief Technical Officer

• Ann Lee, PhD, is the Chief Technical Officer of Prime Medicine.
• She is a biotech executive with extensive experience in the development and manufacturing of vaccines, biologics, small molecules, and cell therapies.
• Dr. Lee has contributed to the licensure and commercialization of 25 new vaccines and medicines, most recently including two CAR T cell therapies during her time at BMS, following its acquisitions of Celgene and Juno Therapeutics.

Niamh Alix Chief Human Resources Officer

• Niamh Alix joined Prime Medicine in June 2022 as Chief Human Resources Officer.
• She brings nearly two decades of experience in human resources, focusing on growing teams from small, early-stage organizations to global enterprises.
• Ms. Alix holds a master's degree in HR strategies from Dublin City University and a B.Sc. in management from the Technological University of Dublin.

Key Risks to the Business of Prime Medicine (PRME)

• Lack of Clinical Validation for Prime Editing Technology: Prime Medicine's core Prime Editing technology is a novel gene editing platform that has not yet been clinically validated for human therapeutic use. The entire business model relies on the successful development and regulatory approval of this unproven technology.
• Dependence on Licensed Intellectual Property from Broad Institute: Prime Medicine's ability to operate and protect its Prime Editing platform is highly dependent on an exclusive license agreement with the Broad Institute. The Broad Institute owns key patents, including the '770 Patent, covering the Prime Editing technology. Any issues with this license, its terms, or the Broad Institute's ownership and enforcement of the underlying patents could severely impact Prime Medicine's business.
• Potential Conflicts of Interest with Co-Founder: A co-founder, Dr. David Liu, has ongoing consulting commitments that accommodate a previous commitment with Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest for Prime Medicine.

A clear emerging threat is posed by **Beam Therapeutics Inc.** (BEAM). Dr. David Liu, a co-founder of Prime Medicine, also has a "previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest." Beam Therapeutics is an established biotechnology company in the gene editing space. This dual affiliation with a key scientific leader suggests an ongoing competitive dynamic where advancements by Beam Therapeutics in gene editing technology or their pipeline programs could directly challenge Prime Medicine's market position, especially given Prime Medicine's claim of superior versatility and precision over existing gene editing platforms.

Prime Medicine (Nasdaq: PRME) is focused on developing one-time curative genetic therapies through its proprietary Prime Editing technology, which aims to address a wide spectrum of diseases caused by genetic mutations.

The addressable market for Prime Medicine's core Prime Editing technology is substantial. Globally, the prime editing market size reached approximately $258.4 million in 2024. This market is projected to experience robust expansion, with a compound annual growth rate (CAGR) of 37.2% from 2025 to 2033, reaching a forecasted value of approximately $3.52 billion by the end of 2033. North America held the largest share of this market in 2024, valued at about $112.6 million. The Asia Pacific region is also a rapidly growing market for prime editing, with a value of approximately $52.1 million in 2024.

Beyond the core technology, Prime Medicine is developing therapies for specific diseases, each with its own addressable market:

• For Chronic Granulomatous Disease (CGD), Prime Medicine's lead ex vivo therapy (PM359) targets a market projected to grow from $1.44 billion in 2025 to $2.2 billion by 2035.
• For Wilson Disease, the six most common mutations account for up to 26,000 patients in addressable markets, including the U.S., Europe, and Japan.
• The in vivo programs targeting Alpha-1 Antitrypsin Deficiency (AATD) are expected to reach a market of $4.4 million by 2035.

Prime Medicine (PRME) is a biotechnology company in the pre-revenue stage from product sales, with its future revenue growth over the next 2-3 years primarily driven by advancements in its gene editing pipeline and strategic collaborations. Key drivers include:

1. Achievement of Preclinical and Clinical Milestones: A significant driver of future revenue will be the successful advancement of Prime Medicine's pipeline programs through preclinical and clinical development. This includes the planned Investigational New Drug (IND) and/or Clinical Trial Application (CTA) filings for its liver-focused programs for Wilson's Disease (PM577) in the first half of 2026 and Alpha-1 Antitrypsin Deficiency (AATD) in mid-2026, with initial clinical data for both anticipated in 2027. These milestones are critical for triggering payments from existing collaborations and attracting new partners.

2. Expansion and Initiation of Strategic Collaborations: Prime Medicine's revenue growth is heavily reliant on strategic partnerships, such as its ongoing collaboration with Bristol Myers Squibb to develop and commercialize Prime Edited ex vivo T-cell therapies. These agreements typically include upfront payments, research funding, and milestone payments upon the achievement of specific development, regulatory, and commercial targets. The company actively seeks additional business development opportunities to leverage its Prime Editing platform across a broader range of indications.

3. Advancement of the Cystic Fibrosis Program: The company is progressing an in vivo Cystic Fibrosis program, supported by funding from the Cystic Fibrosis Foundation. Anticipated generation of preclinical proof-of-concept data in 2026 could attract further funding, partnerships, or lead to milestone payments, contributing to revenue growth.

4. Monetization of the Chronic Granulomatous Disease (CGD) Program: Although Prime Medicine has strong Phase 1/2 clinical data for PM359 in Chronic Granulomatous Disease (CGD) and intends to submit a Biologics License Application (BLA), the company has indicated it is exploring options for external clinical development due to the small patient population and high costs associated with independent commercialization. This suggests potential future revenue through out-licensing, co-development agreements, or other partnerships for PM359.

Share Issuance

Inbound Investments

Capital Expenditures